
# Chapter 1: Genomics to Molecules

This chapter introduces the journey from genomics data to actionable molecular targets in drug discovery. It covers how genetic information is translated into protein targets and how these are linked to small molecules for therapeutic intervention.

---

## Summary

This workflow demonstrates how to start from a gene (e.g., SOD1 for ALS), find the corresponding protein (UniProt), retrieve known small-molecule ligands (ChEMBL), and analyze their molecular properties. This bridges genomics and cheminformatics, enabling rational drug discovery starting from genetic information.


## Key Code Snippets

### 1. Retrieve ALS Target Genes from Open Targets
```python
import requests
efo_id = "Orphanet_803"  # ALS
ot_url = f"https://platform-api.opentargets.io/v3/platform/public/association/filter?disease={efo_id}&size=30&fields=target.gene_info.symbol,target.gene_info.name,association_score.overall"
resp = requests.get(ot_url)
gene_hits = resp.json().get('data', [])
als_genes = [g['target']['gene_info']['symbol'] for g in gene_hits]
print('Top ALS target genes:', als_genes)
```

### 2. Batch Extract Non-Protein Entities from PDB
```python
import requests, pandas as pd
pdb_ids = ['2RSQ', '4RFX', '7WWT', ...]  # your PDB list
all_results = []
for pdb_id in pdb_ids:
	url = f'https://data.rcsb.org/rest/v1/core/entry/{pdb_id}'
	resp = requests.get(url)
	if resp.status_code == 200:
		data = resp.json()
		for entity in data.get('nonpolymer_entities', []):
			chem_comp = entity.get('chem_comp', {})
			all_results.append({
				'pdb_id': pdb_id,
				---

				## Interpretation of Exported Ligands for ALS Drug Discovery

				At the end of this workflow, the notebook exports a file `ligands_for_docking.csv` containing known ligands for the selected ALS target (e.g., SOD1). Here is an example of the exported data:

				| name         | smiles                                                        |
				|--------------|---------------------------------------------------------------|
				| CHEMBL273030 | c1ccc2cc3c(NCCc4c[nH]cn4)nnc(NCCc4c[nH]cn4)c3cc2c1           |
				| CHEMBL272808 | Clc1nnc(NCCc2c[nH]cn2)c2cc3ccccc3cc12                        |
				| CHEMBL272641 | c1ccc2cc3c(NCCCn4ccnc4)nnc(NCCCn4ccnc4)c3cc2c1               |
				| CHEMBL405899 | Clc1nnc(NCCCn2ccnc2)c2cc3ccccc3cc12                          |
				| CHEMBL1672028| c1ccc2cc3c(Nc4cc[nH]n4)nnc(Nc4cc[nH]n4)c3cc2c1               |

				**How to interpret these results:**

				- These ligands are ChEMBL compounds with known bioactivity, retrieved for the ALS target SOD1.
				- Their structures are consistent with CNS drug-like scaffolds, but further ADMET and blood-brain barrier predictions are needed for ALS relevance.
				- These molecules are not validated ALS drugs, but are reasonable starting points for hit discovery and virtual screening.
				- The CSV can be used directly in docking or cheminformatics pipelines to prioritize or design new compounds.

				**Limitations:**
				- The activity data is typically from in vitro assays, not ALS disease models.
				- Further experimental validation is required to confirm efficacy and safety in ALS.

				**Summary:**
				The notebook provides a practical, automated way to go from ALS gene to actionable ligand lists for computational drug discovery, enabling rapid hypothesis generation and screening for ALS research.
				'entity_id': chem_comp.get('id', ''),
				'entity_name': chem_comp.get('name', ''),
				'entity_type': chem_comp.get('type', '')
			})
pd.DataFrame(all_results).to_csv('batch_als_pdb_entities.csv', index=False)
```

### 3. Find Known Ligands for a Target in ChEMBL
```python
from chembl_webresource_client.new_client import new_client
target = new_client.target
activity = new_client.activity
acc = 'P00441'  # UniProt for SOD1
targets = list(target.filter(target_components__accession=acc))
chembl_id = targets[0]['target_chembl_id']
acts = activity.filter(target_chembl_id=chembl_id, standard_type='IC50')
for a in list(acts)[:5]:
	print(a.get('molecule_chembl_id'), a.get('standard_value'))
```


## Notebook Link

For the full workflow, see the interactive notebook: [chapter1-genomics-to-molecules.ipynb](../notebooks/chapter1-genomics-to-molecules.ipynb)


## 1.1 Introduction to Genomics in Drug Discovery
## 1.2 From Genes to Proteins
## 1.3 Target Identification and Validation
## 1.4 Linking Targets to Molecules
## 1.5 Case Study: ALS Gene to Ligand

---

## Interpretation of Exported Ligands for ALS Drug Discovery

At the end of this workflow, the notebook exports a file `ligands_for_docking.csv` containing known ligands for the selected ALS target (e.g., SOD1). Here is an example of the exported data:

| name         | smiles                                                        |
|--------------|---------------------------------------------------------------|
| CHEMBL273030 | c1ccc2cc3c(NCCc4c[nH]cn4)nnc(NCCc4c[nH]cn4)c3cc2c1           |
| CHEMBL272808 | Clc1nnc(NCCc2c[nH]cn2)c2cc3ccccc3cc12                        |
| CHEMBL272641 | c1ccc2cc3c(NCCCn4ccnc4)nnc(NCCCn4ccnc4)c3cc2c1               |
| CHEMBL405899 | Clc1nnc(NCCCn2ccnc2)c2cc3ccccc3cc12                          |
| CHEMBL1672028| c1ccc2cc3c(Nc4cc[nH]n4)nnc(Nc4cc[nH]n4)c3cc2c1               |

**How to interpret these results:**

- These ligands are ChEMBL compounds with known bioactivity, retrieved for the ALS target SOD1.
- Their structures are consistent with CNS drug-like scaffolds, but further ADMET and blood-brain barrier predictions are needed for ALS relevance.
- These molecules are not validated ALS drugs, but are reasonable starting points for hit discovery and virtual screening.
- The CSV can be used directly in docking or cheminformatics pipelines to prioritize or design new compounds.

**Limitations:**
- The activity data is typically from in vitro assays, not ALS disease models.
- Further experimental validation is required to confirm efficacy and safety in ALS.

**Summary:**
The notebook provides a practical, automated way to go from ALS gene to actionable ligand lists for computational drug discovery, enabling rapid hypothesis generation and screening for ALS research.
